Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.
Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.